Home » Agenda


9th RWE, Market Access, Pricing & Reimbursement Global Congress 2023 Europe

4th - 5th May 2023 - Copthorne Tara Hotel London Kensington, London, UK

Thursday 4th - Friday 5th May 2023

Paradigm Global Events is very pleased to welcome you to our upcoming 9th RWE, Market Access, Pricing & Reimbursement Global Congress 2023 Europe

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

The upcoming 2023 RWE, Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “A New Model of Access Strategy for the Next Normal.”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the RWE, MAPR 2023 congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events


  • Take part in meaningful discussions with industry experts and key decision-makers on current trends and best practices
  • Realise the potential of RWE to achieve launch success and optimal market access
  • Learn from your peers about pricing and reimbursement systems in their market
  • Know how to implement a successful market access strategy and how to communicate value to stakeholders
  • Recognise the importance of innovative real-world evidence partnerships for better data
  • Hear an overview of the market access system in place in large pharma markets
  • Gain knowledge of the Market Access environment in Europe’s major markets
  • Find out the role of emerging markets
  • Challenges and opportunities in pricing, reimbursement and patient access
  • Global and European MA trends, collaboration and spillovers
  • Patient-centred approach for better outcome


This Congress will provide information to pharmaceutical and biotech companies, researchers, physicians, institutional review boards (IRBs), patient organizations and advocates, and regulatory agencies about the implementation of Real-World Evidence. 

Network with members of the boards, VP’s, Directors, Heads/Chiefs, and Senior Managers of leading Pharmaceuticals and Biotech Companies, Government, CRO’s and Solution Providers Involved in:

  • Market Access
  • Reimbursement
  • Patient Outcomes
  • Drug Pricing
  • Health Economics and Outcomes Research
  • Payer Relations/ Evidence
  • Regulatory Affairs
  • Public/ Government Affairs
  • Payers, HTA Officials and Physicians
  • Business Development
  • Marketing
  • Commercial Executives
  • Product Launch
  • Real-world Evidence
  • Commercialization
  • Value Strategy
  • Product Strategy
  • Forecaster
  • Finance Officer
  • And much more…


  • Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution


 Dr. Marco Rauland, Vice President, Global Value Demonstration, Market Access & Pricing, Merck KGaA


Libby Hamson, Senior Manager, Market Access, Pfizer
Senior Representative, OPTiMAX Access

  • Current trends in parallel advice: What has changed?
  • Importance of seeking early regulatory, HTA, and joint consultation
  • Risk and advantages of using parallel consultation at the EU or national level?
  • Successful strategies to maximise the benefit of parallel consultation
  • Overview and key aspects
  • Status and timeline
  • EU joint HTA and national submissions
  • Challenges and implications

 Elvira Müller, Vice President, Evidence & Access, CERTARA

  • Impact of the Life Science Strategy Sector Deal
  • NHS 10 Year Plan
  • Future of the UK Government/Industry Voluntary Scheme for Branded medicines.

 Santoke Naal, Director Market Access, IGES U.K. Pharma Ltd

  • When and how to integrate value planning into development
  • Staying responsive to changing market conditions Trends to watch
  • Enabling diverse perspectives through timely engagement

 Esther  Nzenza, Founder and CEO, Decisive Consulting Ltd.

  • Historical use, and impact, of value-based pricing in multi-indication drugs and combination drugs
  • Lessons to be learnt from historical VBP cases
  • Potential avenues to improve on value-based pricing of ‘special’ drug categories
  • Examples of how health systems are adapting their pricing mechanisms

 Mitun Patel, Director, Red Nucleus

 Higia Vassoler, Associate Director, Red Nucleus


  • Plasma-derived medicines (PDMPs) are essential for some 300,000 patients across the EU who rely on these therapies every day to treat a variety of rare, chronic, and life threatening conditions. Without these treatments, many patients would have a substantially diminished quality of life, and some may not survive.
  • PDMPs are a finite resource because the manufacture of these medicines is dependent on the amounts of human plasma collected.
  • Using the AIFA CTS Innovation Algorithm and the WHO Framework for Appropriate Medical Use, a broad range of Key Opinion leaders, in the field of immunology, neurology, rheumatology and dermatology, debated about the appropriate use of Immunoglobulins for their patients. The discussion
    was concluded in a Green Paper developed by Vintura.

 Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association

  • Robust RWE generation to accelerate drug approval and inform clinical practice during a rapidly
    evolving pandemic
  • COVID-19 and the wide-ranging role of RWE in informing decision making: From disease monitoring to
    treatment effectiveness
  • Methodological considerations and cautionary tales of RWE generation in COVID-19
  • Best practices and lessons learned for effectively utilizing RWD/RWE in future pandemics

 Stephane Read, Sr Technical Consultant, Epidemiology, Certara Evidence & Access

  • Recognize the potential of Personalized Medicine in Oncology / Cancer Patients benefits;
  • Identify challenges which could be encountered during HTA process;
  • Develop strategies to overcome or to remove any barrier for Patient Access to Precision Oncology
  • Cost to Society, Health System and Government
  • Technology and Evidence Development

 Rafael Souza, Head, Access Solutions & Pricing, New Markets, BeiGene Switzerland

  • The use of RWD early in the process to boost trial diversity and inclusion
  • Challenge in setting diversity goals early in clinical trial planning
  • Development of a diversity plan to ensure adequate representation of racial and ethnic subgroups in clinical trials
  • Utilizing RWE in the post-marketing setting to complement clinical trial findings and support post marketing requirements or commitments for safety and efficacy data in a diverse patient population

 Riad Dirani, VP of Global HEOR, Medical Operations & Excellence, Teva

  • Regulatory challenges following Brexit and its effect
  • Steps taken by MHRA to alleviate the effects of leaving the European regulatory network.
  • Understanding the current state of pharmaceutical sector
  • Addressing the priorities for negotiations
  • The ability of UK citizens to access new medications


 Matthias Heck, Sr Director, International TA Policy Strategy, Alexion Pharmaceuticals


 Santoke Naal, Director Market Access, IGES U.K. Pharma Ltd


  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

 Claudia Neuber, Head, Global Pricing Oncology, Global Market Access & Pricing, AstraZeneca

  • Access to innovative medicines remains a key issue worldwide
  • Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the expected change in legislation in Europe
  • How can pharmaceutical companies and health authorities work together to bridge the gap

  Silvy  Mardiguian, Market Access Director, UK & Ireland, BeiGene UK

  • Innovative approaches required to address the medicine access challenge
  • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
  • The value of list prices against the backdrop of external price referencing and managed entry agreements.
  • Innovative policy options that needs to be developed, agreed upon and implemented.

 Josie Godfrey, Co-Founder and CEO, Realise Advocacy, Director, JG Zebra Consulting

  • One of the most overlooked activities in the entire market access flow is tendering, a successful access is measured
    on how the medicine reaches the patients, however an increasing amount of countries are using tenders to add
    additional pressure on the procurement of the therapies, not having an adequate process in place can jeopardize
    access plans and can have unexpected consequences abroad

 Frankie Shupo, Global Director, Market Access and HEOR, EUSA Pharma

  • Role of market access within the organization and importance of market access capabilities;
  • Building “market access mindset” for cross-functional business partners;
  • Evolving capabilities for future market access leaders

 Maria Danchenko, Global Market Access Academy Lead, Sanofi

 Daniel Jackson, Global Head – Market Access Policy, UCB 

  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations

Antje Emmermann, Executive Director, Market Access Lead, Alexion


  • One of the most overlooked activities in the entire market access flow is tendering, a successful access is measured
    on how the medicine reaches the patients, however an increasing amount of countries are using tenders to add
    additional pressure on the procurement of the therapies, not having an adequate process in place can jeopardize
    access plans and can have unexpected consequences abroad.

 Ryotaro Ishikawa, Global Market Access Director, Novartis

  • As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
  • what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ?
  • If the drugs dont work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
  • Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities for innovative contracting

 Omar Ali, Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines, University of Portsmouth

  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?


Maria Danchenko, Global Market Access Academy Lead, Sanofi

 Daniel Jackson, Global Head – Market Access Policy, UCB

Scroll to Top